-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target

Benzinga·06/18/2026 17:02:13
Listen to the news
Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.